| NCT06982508 | Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers | NOT_YET_RECRUITING | PHASE2 | 2025-08 | 2026-06 | 2026-04 |
| NCT06496243 | Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | RECRUITING | PHASE2 | 2024-12-02 | 2026-02 | 2025-11 |
| NCT06547359 | A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects | COMPLETED | PHASE1 | 2024-10-01 | 2024-11-12 | 2024-11-12 |
| NCT06305559 | A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | RECRUITING | PHASE3 | 2024-05-16 | 2027-03 | 2026-12 |
| NCT06005597 | Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies | COMPLETED | PHASE3 | 2024-03-01 | 2024-10-16 | 2024-09-25 |
| NCT06250205 | Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib | COMPLETED | PHASE1 | 2024-02-05 | 2024-04-26 | 2024-04-25 |
| NCT06050291 | Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe | COMPLETED | PHASE1 | 2024-01-20 | 2024-04-07 | 2024-04-07 |
| NCT05972278 | Investigating the Effect of Obicetrapib on Lipoprotein Metabolism | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-12-01 | 2024-10-14 | 2024-09-26 |
| NCT06048302 | PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function | COMPLETED | PHASE1 | 2023-11-30 | 2024-03-19 | 2024-03-12 |
| NCT06081166 | A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin | COMPLETED | PHASE1 | 2023-11-11 | 2024-01-22 | 2023-12-02 |
| NCT05425745 | Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. | COMPLETED | PHASE3 | 2022-07-25 | 2024-05-28 | 2024-05-28 |
| NCT05421078 | A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. | COMPLETED | PHASE2 | 2022-06-27 | 2023-04-21 | 2023-03-24 |
| NCT05266586 | Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy | COMPLETED | PHASE2 | 2022-03-09 | 2022-09-08 | 2022-08-12 |
| NCT05202509 | Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-02-07 | 2026-11 | 2026-11 |
| NCT05161715 | Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease | COMPLETED | PHASE2 | 2022-01-12 | 2023-06-01 | 2023-05-09 |
| NCT05142722 | Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies | COMPLETED | PHASE3 | 2021-12-15 | 2024-09-26 | 2024-09-26 |
| NCT04770389 | Randomized Study of Obicetrapib in Combination With Ezetimibe | COMPLETED | PHASE2 | 2021-02-23 | 2021-06-30 | 2021-05-07 |
| NCT04753606 | Randomized Study of Obicetrapib as an Adjunct to Statin Therapy | COMPLETED | PHASE2 | 2021-02-18 | 2021-08-30 | 2021-05-24 |